ALGS Stock — Aligos Therapeutics Inc.: Cash, EV, Pipeline

Share price

$5.24

Market cap

$32.7M

Cash

$30.4M

Enterprise value

$2.3M

Balance sheet

Cash	$30.4M
Debt	$0.0M
Net cash	$30.4M
Enterprise value	$2.3M
Basic shares	6.2M shares
Fully diluted shares	16.9M shares
Fully diluted market cap	$88.5M
Cash per share	$4.90

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ALGS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	ALG-000184	Phase 2	Chronic Hepatitis B Infection	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Pevifoscorvir sodium

Phase 2 · Active Modality: small molecule

Aliases ALG-000184

Target HBV capsid assembly (CAM-E)

Partnerships Xiamen Amoytop Biotech Co., Ltd: exclusive Greater China license, $25.0M upfront (net of tax, received Jul 2026), up to $420M in clinical/regulatory/sales milestones, tiered high single-digit royalties

Indications

Chronic HBV infection (Phase 2)

Catalysts

— late Q3 2027

Status note Phase 2 B-SUPREME study (NCT06963710, ~250 subjects, 48-week monotherapy vs tenofovir disoproxil fumarate) enrollment completed (131 HBeAg+ Part 1a, 114 HBeAg- Part 2a). Received FDA Fast Track Designation and China NMPA/CDE Breakthrough Therapy Designation for chronic HBV infection.

ALG-170675

Preclinical · Active Modality: antisense oligonucleotide (ASO)

Target HBV RNA transcripts (HBsAg mRNA); also TLR8 agonist activity

Partnerships Xiamen Amoytop Biotech Co., Ltd: research collaboration; Amoytop holds Greater China rights and funds China development; earned $3.0M milestone at IND-enabling start (Jan 2026) and $3.0M at China IND approval (Jul 2026); eligible for up to $109.0M in development/commercialization milestones plus tiered royalties

Indications

Chronic HBV infection (Preclinical)

Catalysts

— Q3 2026

Status note Next-generation ASO discovered under Amoytop collaboration. Amoytop received IND approval in China in July 2026; Phase 1 in healthy volunteers with planned HBV-infected cohort (following 150 mg MAD cohort, Q4 2026) to be sponsored and performed by Amoytop. Each party funds its own development; Aligos may run a Phase 2 in 2028.

ALG-055009

Phase 2 · Active Modality: small molecule

Target Thyroid hormone receptor beta (THR-beta)

Indications

Metabolic dysfunction-associated steatohepatitis (MASH) (Phase 2)
Obesity (Preclinical)

Status note Phase 2a HERALD study (2024) completed. Obesity work is preclinical (diet-induced obese mouse data for combination with incretin receptor agonists). Company is evaluating options to fund continued development, including potential out-licensing; not explicitly discontinued.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ALG-000184
Lead indication	Chronic Hepatitis B Infection
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06963710	Phase 2	Active, not recruiting	Sponsor	Aligos Therapeutics	—	Chronic Hepatitis B Infection	—
NCT06672900	Phase 1	Active, not recruiting	Sponsor	Aligos Therapeutics	—	Healthy Volunteer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Aligos Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	83,055	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ALGS — Aligos Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders